Provided is a solid oral pharmaceutical composition comprising two tablet formulations. The first tablet formulation, in the form of at least one micro-tablet, comprises a core comprising at least one Krebs cycle precursor salt and a coating comprising at least one coating agent. The second tablet formulation, in the form of at least one mini-tablet, comprises a core comprising at least one bicarbonate salt and at least one sustained-release hydrophilic matrix and a coating comprising at least one coating agent. A preferred Krebs cycle precursor salt is potassium citrate. A preferred bicarbonate salt is potassium bicarbonate. Further provided is the use of the pharmaceutical composition as a medicament, in particular in the treatment and/or prevention of cystinuria.
